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Abstract 
Development of Donor Specific Antibodies (DSA) is linked to worsened outcomes in renal transplant 
recipients.  Intravenous immunoglobulin (IVIG) is an immune-modulator utilized in treatment of 
antibody mediated rejection.  A retrospective review of kidney transplant cases at Lehigh Valley Health 
Network (LVHN) from January 2009 to June 2014 was performed to evaluate the efficacy of IVIG in 
treatment of new DSAs. All patients undergoing renal transplant at LVHN are cross-match compatible at 
the time of procedure.  Desensitization is not utilized.  All highly sensitized patients (PRA>50%) receive 
prophylactic IVIG monthly x 4 months post-transplant.  Study patients that tested positive for DSA post-
transplant were treated with additional IVIG (0.5g/kg monthly).  95 patients were treated with IVIG 
during the study period.  Of 55 patients with newly positive DSA, 24 of these cleared the DSA after IVIG 
treatment.  IVIG was more effective in clearance of class I than class II DSA. Highest rates of graft loss 
occurred in patients that tested positive for both a class I and class II DSA. Conclusion:   1. IVIG can be a 
useful in eliminating DSA post-renal transplant.  2. IVIG is effective in eliminating Class I DSA.  3.  Class II 
DSA can be difficult to eliminate and requires further investigation. 
Background 
Intravenous immunoglobulin (IVIG) is a medication that has emerged as a useful tool in modulating 
immunity, treatment of antibody mediated rejection (AMR), and in desensitization protocols. IVIG 
serves as a mediator of the immune system and as a regulator of inflammation.  DSAs specifically target 
the transplant donor organ. The presence of DSAs has been linked to significantly worse graft survival.  
In patients with AMR, therapy with IVIG paired rituximab and plasmapheresis (PP) can increase graft 
survival by more than 40% and suppress DSAs. (1) Studies have still not demonstrated optimal regimens 
for treatment of new DSA. The purpose of this study was to investigate the effectiveness of IVIG in 
elimination of DSAs. 
 
Methodology 
A retrospective chart review was performed of all kidney transplant patients at Lehigh Valley Health 
Network who were treated with IVIG post transplantation from January 2009 to June 2014. All patients 
were cross match compatible (no DSA presence at time of transplant) and had not undergone 
desensitization protocols.  All highly sensitized patients (PRA greater than 50%), were prophylactically 
treated with 0.5g/kg of IVIG monthly for four doses beginning at the time of transplant per the center’s 
protocol. These patients had monthly DSA tests for at least one year. Nonsensitized patients (PRA less 
than 50%) did not receive prophylactic IVIG. These patients were checked for DSAs after 1, 6, and 12 
months and when symptoms arose (elevated creatinine, proteinuria).  
Patients that tested positive for DSA post-transplant were treated monthly with 0.5g/kg of IVIG until 
clearance of DSA. These patients also underwent renal transplant biopsy at discovery of DSA. Successful 
treatment was considered elimination of DSA for greater than 1 month.  Time to DSA clearance, dates of 




Of the 293 patients who received kidney transplantation at Lehigh Valley Health Network in the study 
period, 95 were treated with IVIG.  55 patients that were treated with IVIG had a positive DSA (57.8%).  
24 (43.6%) of those patients cleared the DSA after treatment with IVIG. Of the remaining 31 patients, 28 
did not clear the DSA and 3 patients expired during the study interval. 
61 of the 95 (64.2%) patients received prophylactic IVIG. Out of those, 41/61 (67.2%) never developed a 
DSA while 20/61 (32.8%) did. Out of the 20 that developed a DSA, 9 cleared the DSA.  34 non-sensitized 
patients (12% total non-sensitized transplants) developed DSAs and then received treatment with IVIG.   
 
 







Prophylactic IVIG (Sensitized patients) Non Prophylactic patients (nonsensitized) 
Total Patients                                                                   61/95                                                                              34/95
Total percent 64.20% 35.80%
New DSA                                                            32.8% (20) 100%
DSA clearence                                                            45% (9/20)                                                              44.1% (15/34)
AMR                                                           35% (7/20)                                                               64.7% (22/34)
DSA Cleared DSA % Average days positive Graft loss but patient alive Death while graft functional AMR
Class I (12) Yes 66.7% (8/12) 164 12.5% (1/8) 0% (0/8) 37.5% (3/8)
No 33.3% (4/12) 544 0% (0/4)  0% (0/4) 0% (0/4)
Class II (26) Yes 42.3% (11/26) 85  9% (1/11) 0% (0/11)  18.2% (2/11)
No 57.7% (15/26) 883  20% (3/15)  6.7% (1/15)  60% (9/15)
Class I and Class II Both 23.5% (4/17) 739  28.6% (2/7) 28.6% (2/7) 100% (7/7)
Neither 29.4% (5/17) 613 33.3% (4/12) 16.7% (2/12) 100% (4/4)
Class I only  41.2% (7/17) 1039  20% (1/5) 40% (2/5)  80% (4/5)
Class II only 6% (1/17)                                          *66 0% (0/1) 100% (1/1)  0% (0/1)
Outcomes of Class I versus Class II DSAs Treated with IVIG 
 
 
IVIG was more effective in the clearance of class I DSA’s than class II.  Following treatment with IVIG, 
8/12 (66.7%) of the Class I DSAs cleared and 11/26 (42.3%) of the class II DSAs cleared (p=0.05).   
Clearance rates were lower in patients starting with both Class I and II antibodies, but Class I cleared 
more frequently.  In only one case, the patient cleared the class II DSA first, however this patient expired 
only two months later while the class I was still present. Lowest rates of graft loss occurred in patients 



























1.  IVIG can be a useful in eliminating DSA post-renal transplant.   
2. IVIG is effective in eliminating Class I DSA.   
3.   Presence of Class II DSA is associated with higher rates of graft loss.  Class II DSA can be difficult to 
eliminate and requires further investigation, possibly in combination with biologic agents. 
4.  Limited numbers of patients at this time make statistically significant results difficult to achieve.  
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